

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims

1. (Currently amended) ~~Compound chosen~~ A compound from the following compounds:
- butyl 2-[4-(4-aminophenyl)-1*H*-imidazol-2-yl]ethylcarbamate;
 - N*,2-dimethyl-1-[4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propan-1-amine;
 - *N*,2-dimethyl-1-[4-(10*H*-phenoxazin-2-yl)-1,3-thiazol-2-yl]propan-1-amine;
 - *N*,3-dimethyl-1-[4-(10*H*-phenoxazin-2-yl)-1,3-thiazol-2-yl]butan-1-amine;
 - *N*,3-dimethyl-1-[4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]butan-1-amine;
 - 2,6-di-*tert*-butyl-4-{2-[3-methyl-1-(methylamino)butyl]-1,3-thiazol-4-yl}phenol;
 - [4-(3,5-di-*tert*-butylphenyl)-1,3-thiazol-2-yl]methylamine;
 - 2,6-di-*tert*-butyl-4-{2-[(*IS*)-1-(methylamino)ethyl]-1,3-thiazol-4-yl}phenol;
 - 2,6-di-*tert*-butyl-4-{2-[(*IR*)-1-(methylamino)ethyl]-1,3-thiazol-4-yl}phenol;
 - *N*-{[4-(3,5-di-*tert*-butylphenyl)-1,3-thiazol-2-yl]methyl}-*N*-methylamine;
 - *N*-methyl-*N*-{[4-(3,4,5-trimethoxyphenyl)-1,3-thiazol-2-yl]methyl}amine;
 - ethyl *N*-{[4-(3,5-di-*tert*-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}glycinate;
 - *N*-{[4-(3,5-di-*tert*-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}glycine;
 - 2,6-di-*tert*-butyl-4-{2-[(4-methoxypiperidin-1-yl)methyl]-1,3-thiazol-4-yl}phenol;
 - *N*-methyl-*N*-{(*IS*)-2-methyl-1-[4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propyl}amine;
 - *N*,2-dimethyl-1-[4-(10-methyl-10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propan-1-amine;
 - *N*-methyl-*N*-{(*IS*)-2-methyl-1-[4-(10*H*-phenoxazin-2-yl)-1,3-thiazol-2-yl]propyl}amine;
 - 4-{2-[(*IR*)-1-aminoethyl]-1,3-thiazol-4-yl}-2,6-di-*tert*-butylphenol;
 - 4-{2-[(*IS*)-1-aminoethyl]-1,3-thiazol-4-yl}-2,6-di-*tert*-butylphenol;

- 4-[2-(1-aminocyclopropyl)-1,3-thiazol-4-yl]-2,6-di-*tert*-butylphenol;
 - 4-{2-[(methylamino)methyl]-1,3-thiazol-4-yl}benzene-1,2-diol;
 - *N*-methyl-*N*-{(1*R*)-2-methyl-1-[4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propyl}amine;
 - (1*R*)-2-methyl-1-[4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propan-1-amine;
 - *N*-methyl-*N*-{(1*R*)-2-methyl-1-[4-(10*H*-phenoxazin-2-yl)-1,3-thiazol-2-yl]propyl}amine;
 - *N*²-{[4-(3,5-di-*tert*-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}glycinamide;
 - ethyl *N*-{[4-(3,5-di-*tert*-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}-*N*-(2-ethoxy-2-oxoethyl)glycinate;
 - 4-(3,5-di-*tert*-butyl-4-methoxyphenyl)-2-(methoxymethyl)-1,3-thiazole;
 - 4-[2-(1-aminocyclopentyl)-1,3-thiazol-4-yl]-2,6-di-*tert*-butylphenol;
- or a salts or combinations thereof ~~of one of the latter~~.

2. (Currently amended) A compound ~~or salt~~ according to claim 1, ~~characterized in that it~~ wherein the compound is butyl 2-[4-(4-aminophenyl)-1*H*-imidazol-2-yl]ethylcarbamate or a salt thereof ~~one of its salts~~.

3. (Currently amended) A compound or salt according to claim 1, ~~characterized in that it~~ wherein the compound is 4-[2-(1-aminocyclopentyl)-1,3-thiazol-4-yl]-2,6-di-*tert*-butylphenol or a salt thereof ~~one of its salts~~.

4. (Currently amended) As a medicament, comprising a compound ~~chosen from the following compounds~~:

- butyl 2-[4-(4-aminophenyl)-1*H*-imidazol-2-yl]ethylcarbamate;
- *N*,2-dimethyl-1-[4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]propan-1-amine;
- *N*,2-dimethyl-1-[4-(10*H*-phenoxazin-2-yl)-1,3-thiazol-2-yl]propan-1-amine;
- *N*,3-dimethyl-1-[4-(10*H*-phenoxazin-2-yl)-1,3-thiazol-2-yl]butan-1-amine;
- *N*,3-dimethyl-1-[4-(10*H*-phenothiazin-2-yl)-1,3-thiazol-2-yl]butan-1-amine;
- 2,6-di-*tert*-butyl-4-{2-[3-methyl-1-(methylamino)butyl]-1,3-thiazol-4-yl}phenol;

- [4-(3,5-di-*tert*-butylphenyl)-1,3-thiazol-2-yl]methylaniline;
- 2,6-di-*tert*-butyl-4-{2-[(*IS*)-1-(methylaniline)ethyl]-1,3-thiazol-4-yl}phenol;
- 2,6-di-*tert*-butyl-4-{2-[(*IR*)-1-(methylaniline)ethyl]-1,3-thiazol-4-yl}phenol;
- *N*-{[4-(3,5-di-*tert*-butylphenyl)-1,3-thiazol-2-yl]methyl}-*N*-methylaniline;
- *N*-methyl-*N*-{[4-(3,4,5-trimethoxyphenyl)-1,3-thiazol-2-yl]methyl}amine;
- ethyl *N*-{[4-(3,5-di-*tert*-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}glycinate;
- *N*-{[4-(3,5-di-*tert*-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}glycine;
- 2,6-di-*tert*-butyl-4-{2-[(4-methoxypiperidin-1-yl)methyl]-1,3-thiazol-4-yl}phenol;
- *N*-methyl-*N*-{(*IS*)-2-methyl-1-[4-(10H-phenothiazin-2-yl)-1,3-thiazol-2-yl]propyl}amine;
- *N*,2-dimethyl-1-[4-(10-methyl-10H-phenothiazin-2-yl)-1,3-thiazol-2-yl]propan-1-amine;
- *N*-methyl-*N*-{(*IS*)-2-methyl-1-[4-(10H-phenoxazin-2-yl)-1,3-thiazol-2-yl]propyl}amine;
- 4-{2-[(*IR*)-1-aminoethyl]-1,3-thiazol-4-yl}-2,6-di-*tert*-butylphenol;
- 4-{2-[(*IS*)-1-aminoethyl]-1,3-thiazol-4-yl}-2,6-di-*tert*-butylphenol;
- 4-[2-(1-aminocyclopropyl)-1,3-thiazol-4-yl]-2,6-di-*tert*-butylphenol;
- 4-{2-[(methylaniline)methyl]-1,3-thiazol-4-yl}benzene-1,2-diol;
- *N*-methyl-*N*-{(*IR*)-2-methyl-1-[4-(10H-phenothiazin-2-yl)-1,3-thiazol-2-yl]propyl}amine;
- (*IR*)-2-methyl-1-[4-(10H-phenothiazin-2-yl)-1,3-thiazol-2-yl]propan-1-amine;
- *N*-methyl-*N*-{(*IR*)-2-methyl-1-[4-(10H-phenoxazin-2-yl)-1,3-thiazol-2-yl]propyl}amine;
- *N*²-{[4-(3,5-di-*tert*-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}glycinamide;
- ethyl *N*-{[4-(3,5-di-*tert*-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}-*N*-(2-ethoxy-2-oxoethyl)glycinate;
- 4-(3,5-di-*tert*-butyl-4-methoxyphenyl)-2-(methoxymethyl)-1,3-thiazole;
- 4-(2-(1-aminocyclopentyl)-1,3-thiazol-4-yl)-2,6-di-*tert*-butylphenol;

or a pharmaceutically acceptable salts or combinations thereof ~~of one of the latter~~.

5. (Currently amended) ~~A pharmaceutical~~ Pharmaceutical composition comprising ~~containing~~, as an active ingredient, at least one of the compounds or pharmaceutically acceptable salts of ~~mentioned in~~ claim 4.

6. (Currently amended) ~~Use of~~ A method of treating disorders/pathologies selected from neurodegenerative diseases, pain, or epilepsy comprising administering a medicament to a patient, wherein the medicament comprises one of the compounds or pharmaceutically acceptable salts mentioned in of claim 4 ~~for preparing a medicament intended to treat disorders / pathologies chosen from neurodegenerative diseases, pain and epilepsy.~~

7. (Currently amended) ~~Use according to~~ The method of claim 6, wherein the disorders/pathologies treated are ~~characterized in that the medicament prepared is intended to treat~~ neurodegenerative diseases.

8. (Currently amended) ~~Use according to~~ The method of claim 7, ~~characterized in that~~ wherein the compound or pharmaceutically acceptable salt ~~used is chosen from~~ 4-[2-(1-aminocyclopentyl)-1,3-thiazol-4-yl)-2,6-di-*tert*-butylphenol ~~and~~ or pharmaceutically acceptable salts thereof.

9. (Currently amended) ~~Use according to~~ The method of claim 6, comprising ~~treating characterized in that the medicament prepared is intended to treat~~ pain.

10. (Currently amended) ~~Use according to~~ The method of claim 9, ~~characterized in that~~ wherein the compound or pharmaceutically acceptable salt ~~used is chosen from~~ butyl 2-[4-(4-aminophenyl)-1*H*-imidazol-2-yl)ethylcarbamate ~~and~~ or pharmaceutically acceptable salts thereof